Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
- Drug Discovery
- Medical Info
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 305895
Licensor has developed certain inventions and technology related to the use of engineered DNA binding proteins and is the owner of all right, title, and interest in these inventions and technology, developed by its employees and is responsible for their protection and commercial development. Licensors goal is to make them available in commerce for use.
IPSCIO Record ID: 203310
Licensor will generate and deliver to Licensee two complete copies of a library consisting of three hundred fifty thousand (350,000) mouse embryonic stem cell clones with Selected Mutations, each identified by DNA sequence of its genomic integration site, the OmniBank II Library. Subject to the terms of this Agreement, Licensor will use Diligent Efforts to generate and deliver the OmniBank II Library in accordance with the schedule set forth in the Development Plan.
Licensor grants to Licensee the non-transferable, non-exclusive right under Licensors rights in the Cre-Lox Patents to use, breed and cross-breed Mutant Mice and Progeny that contain one or more lox sites in their genome (Lox Mice), at the internal research facilities of Licensee, solely for research purposes.
Licensor grants to Licensee a worldwide, non-exclusive right and license to use the Bioinformatics Software, under the copyrights and know-how Controlled by Licensor with respect thereto. Licensee shall have the right under the foregoing license to custom configure the Bioinformatics Software for its internal use.
The Bioinformatics Software means the software for the management and analysis of data relating to the OmniBank II Library and the production, genotyping and phenotypic analysis of knockout mice.
The library, constructed using Licensor's proprietary mouse gene knockout technology, will enable a researcher to develop a mouse that has a specific gene removed or â€œknocked-out.â€ The function of that gene can then be studied by comparing the knockout mouse to a normal mouse. Approximately 99 percent of human genes have a mouse counterpart, and research using this technology may lead to the development of drugs for a wide variety of human and animal diseases, including diabetes and obesity, infectious disease, cancer and heart disease. Institute researchers will have certain rights to utilize Lexiconâ€™s patented gene targeting technologies. In addition, Licensor will equip the Institute with the bioinformatics software required for the management and analysis of data relating to the library.
IPSCIO Record ID: 294001
A zinc finger is a small protein structural motif that is characterized by the coordination of one or more zinc ions in order to stabilize the fold. Zinc finger proteins are among the most abundant proteins in eukaryotic genomes. Their functions are extraordinarily diverse and include DNA recognition, RNA packaging, transcriptional activation, regulation of apoptosis, protein folding and assembly, and lipid binding.
The Licensor has patent rights in respect of methods of selecting and designing polypeptides comprising zinc finger binding motifs and polypeptides made by those methods.
IPSCIO Record ID: 372419
Gene therapy shall mean the use of a vector containing at least one DNA sequence that encodes at least one protein or other molecule, in order to restore the functional activity of one or more resident non-functional gene copies, or provide for the introduction and expression of novel protein(s) or molecule(s) not normally expressed in the cell type or expression of protein(s) or molecule(s) that do not exist normally in nature. The introduced protein(s) or molecule(s) are not intended to generate a prophylactic and/or therapeutic immune response against the protein or molecule encoded by the introduced DNA sequence of interest for use in Vaccination.
Chimeric antigen receptor cells is a special receptor created in the laboratory that is designed to bind to certain proteins on cancer cells. The chimeric antigen receptor is then added to immune cells called T cells.
IPSCIO Record ID: 237233
Licensor grants a non-exclusive, worldwide license to Licensor Patent Rights, Technology and Improvements to research, develop, make, have made, use, import, offer to sell and sell collaboration products and non-collaboration products in the Field of Use and to sublicense solely the research, development, manufacture, use, importation and sale of such collaboration products and non-collaboration products in the Field of Use.
Licensor grants an exclusive, worldwide license to research, develop, make, have made, use, import, offer to sell and sell collaboration products in the Field of Use and to sublicense the research, development, manufacture, use, importation and sale of such collaboration products in the Field of Use.
Licensor grants a non-exclusive, worldwide license to Licensor Patent Rights to research, develop, make, have made, use, import, offer to sell and sell non-Licensor products in the Field of Use and to sublicense solely the research, development, manufacture, use, importation and sale of such non-Licensor products in the Field of Use.
The patents relate to Gene encoding and novel protein binding, but specifically exclude Claim 66 in U.S. Patent No. 5,223,409 to the extent that it covers DNA molecules encoding single chain antibodies, or (ii) any claim to specific protein or peptide sequences, or nucleic acids encoding the same, that bind to a specific biological or molecular target.
Research Reagent Field shall mean the use of one or more peptides, antibodies, or antibody-antigen or peptide-target combinations (whether in a microarray format or other format) for research purposes.
Therapeutic Field shall mean all human therapeutic and prophylactic uses, and any in vivo diagnostic uses for a Licensee Target which is necessary for HGS successful commercialization of a human therapeutic or prophylactic Collaboration Product, non-collaboration product or non-Licensor product.
Diagnostic Field shall mean all in vitro research, analysis, detection or diagnostic uses, and not for any in vivo diagnostic, therapeutic, purification_ or separations, agricultural, industrial enzyme or other uses.
Licensor Field shall mean all agricultural, industrial enzyme, and purification and separation uses.